Intra Cellular Therapies | ITCI - Net Income


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview

Intra Cellular Therapies

Intra Cellular Therapies reported $-44053000 in Net Income for its fiscal quarter ending in March of 2023.


Net Income Change
Acadia Pharmaceuticals ACAD:US USD -43021000 1.3M
ALKERMES ALKS:US USD -41845000 13.59M
BioCryst Pharmaceuticals BCRX:US USD -53333000 18.21M
Biogen BIIB:US USD 387.9M 162.5M
Bristol-Myers Squibb BMY:US USD 2.26B 240M
Esperion Therapeutics ESPR:US USD -61719000 6.23M
Gilead Sciences GILD:US USD 1.01B 630M
Halozyme Therapeutics HALO:US USD 39.61M 18.09M
Intra Cellular Therapies ITCI:US USD -44053000 27K
J&J JNJ:US USD -68000000 3.59B
Marinus Pharmaceuticals MRNS:US USD -34730000 418K
Minerva Neurosciences NERV:US USD -6970000 244K
Nektar Therapeutics NKTR:US USD -137018000 77.33M
Neurocrine Biosciences NBIX:US USD -76600000 165.6M
Novartis NVS:US USD 2.29B 827M
RedHill Biopharma RDHL:US USD -3729000 31.97M
Supernus Pharmaceuticals SUPN:US USD 16.95M 8.53M
United Therapeutics UTHR:US USD 240.9M 108.8M